FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk

The FDA found no significant increase in risk of serious asthma outcomes combining long-acting beta agonists (LABAs) and inhaled corticosteroids (ICS)
ReachMD Healthcare Image
Media formats available
  • Completing the pre-test is required to access this content.
    Pre-Survey
    Completing the pre-survey is required to access this content.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free